Calyxha is developing novel small molecule anti-inflammatory drugs.
CAL-4 is being developed by Calyxha as an inhaled drug initially for asthma, and is due to enter the clinic in 2023. CAL-4 is predicted to bring the benefit of steroid treatment, but without affecting the cellular pathways involved in steroid side-effects.
CAL-4 is a calixarene small molecule drug identified by Calyxha’s CSO, Professor Robert Konrat using a computation approach integrating several software tools and novel biological pathways to identify potential novel anti-inflammatory drugs.
CAL-4 acts as an inflammatory inhibitor through mimicking the naturally occuring heparan sulphate.